A number of firms have modified their ratings and price targets on shares of OncoCyte (NASDAQ: OCX) recently:
- 10/21/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 10/15/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 10/15/2024 – OncoCyte had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $4.25 price target on the stock.
- 10/9/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 10/3/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 9/27/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 9/21/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 9/15/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 9/9/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 9/3/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 8/28/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
- 8/22/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
OncoCyte Trading Up 0.3 %
Shares of OCX stock opened at $3.13 on Monday. The firm’s fifty day moving average price is $3.08 and its two-hundred day moving average price is $2.94. OncoCyte Co. has a 1 year low of $2.08 and a 1 year high of $4.34.
OncoCyte (NASDAQ:OCX – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%. The company had revenue of $0.10 million during the quarter.
Insider Buying and Selling
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
Recommended Stories
- Five stocks we like better than OncoCyte
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Is Spotify Stock Poised to Soar? Options Traders Think So
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- What is Short Interest? How to Use It
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for OncoCyte Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Co and related companies with MarketBeat.com's FREE daily email newsletter.